Mirati Therapeutics (MRTX) Stock Forecast for 2024–2028. Sell or Buy Prediction







Maximizing Profits: When is the Right Time to Sell Your Business?

April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?

Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
How ZIM Integrated Container Tracking is Revolutionizing Global Trade

April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade

Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…

Mirati Therapeutics (MRTX) Stock Forecast for 2024–2028. Sell or Buy?

Updated: June 16, 2024 (12:38)

Sector: Healthcare

The share price of Mirati Therapeutics, Inc. (MRTX) now

This company is DELISTED
Latest session on the 23rd of January for
Mirati Therapeutics, Inc. is negative
Trading Volume: 0
Open: 58.7 /  High: 58.7 /  Low: 58.7
What analysts predict: $
52-week High/Low: $ / $

50/200 Day Moving Average: $ / $

This figure corresponds to the Average Price over the previous 50/200 days. For Mirati Therapeutics stocks, the 50-day moving average is the support level today.

For Mirati Therapeutics stocks, the 200-day moving average is the support level today.

Are you interested in Mirati Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Mirati Therapeutics stock price in 2024, 2025, 2026, 2027, 2028. How much will one Mirati Therapeutics share be worth in 2024 - 2028?

When should I take profit in Mirati Therapeutics stock? When should I record a loss on Mirati Therapeutics stock? What are analysts' forecasts for Mirati Therapeutics stock? What is the future of Mirati Therapeutics stock? We forecast Mirati Therapeutics stock performance using neural networks based on historical data on Mirati Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Mirati Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Mirati Therapeutics shares. This happens once a day.


Historical and forecast chart of Mirati Therapeutics stock

The chart below shows the historical price of Mirati Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Mirati Therapeutics stock price can be found in the table below.

No data

Long-term forecasts by years.

Mirati Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is focused on developing a pipeline of targeted cancer drugs. The company is developing candidate products to combat genetic and immunological cancer promoters. Its clinical programs consist of two candidate products: MRTX849, a Kirsten rat sarcoma inhibitor (KRAS) G12C, and Sitravatinib, a multi-kinase inhibitor. His KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit the KRAS G12C mutations that are present in patients with non-small cell lung cancer (NSCLC), adenocarcinoma, colorectal cancer (CRC), pancreatic cancer, and several other intractable cancers. Sitravatinib is a spectrally selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs) including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.

Mirati Therapeutics daily forecast for a month

Date Target Pes. Opt. Vol., %
Jun 18 60.94 60.12 61.76 2.74
Jun 19 60.54 59.90 60.92 1.70
Jun 20 59.30 58.41 59.89 2.53
Jun 21 59.00 57.74 59.58 3.19
Jun 22 59.58 58.92 60.80 3.19
Jun 23 60.17 58.84 61.37 4.30
Jun 24 59.78 58.50 61.19 4.60
Jun 25 59.58 58.53 61.01 4.25
Jun 26 58.36 57.59 59.45 3.22
Jun 27 57.44 56.26 58.33 3.68
Jun 28 58.23 57.25 58.82 2.75
Jun 29 59.75 58.89 60.93 3.47
Jun 30 61.13 60.21 62.36 3.56
Jul 01 61.95 60.80 63.16 3.88
Jul 02 61.06 60.53 62.53 3.30
Jul 03 60.95 59.75 61.54 3.00
Jul 04 62.49 61.85 63.58 2.79
Jul 05 63.16 62.46 64.45 3.19
Jul 06 62.37 61.24 62.97 2.81
Jul 07 61.30 60.55 62.61 3.40
Jul 08 61.78 61.37 63.26 3.08
Jul 09 61.82 61.45 62.58 1.84
Jul 10 61.78 60.83 62.63 2.96
Jul 11 63.17 62.37 63.66 2.07
Jul 12 64.04 63.04 65.48 3.87
Jul 13 65.44 64.56 66.70 3.31
Jul 14 64.60 64.13 65.63 2.33
Jul 15 64.21 63.83 64.67 1.33
Jul 16 63.07 61.58 63.77 3.56
Jul 17 63.23 62.83 64.46 2.60

Mirati Therapeutics Daily Price Targets


Mirati Therapeutics Stock Forecast 06-18-2024.

Forecast target price for 06-18-2024: $60.94.
Positive dynamics for Mirati Therapeutics shares will prevail with possible volatility of 2.664%.
Pessimistic target level: 60.12
Optimistic target level: 61.76

Mirati Therapeutics Stock Forecast 06-19-2024.

Forecast target price for 06-19-2024: $60.54.
Negative dynamics for Mirati Therapeutics shares will prevail with possible volatility of 1.669%.
Pessimistic target level: 59.90
Optimistic target level: 60.92

Mirati Therapeutics Stock Forecast 06-20-2024.

Forecast target price for 06-20-2024: $59.30.
Negative dynamics for Mirati Therapeutics shares will prevail with possible volatility of 2.466%.
Pessimistic target level: 58.41
Optimistic target level: 59.89

Mirati Therapeutics Stock Forecast 06-21-2024.

Forecast target price for 06-21-2024: $59.00.
Negative dynamics for Mirati Therapeutics shares will prevail with possible volatility of 3.089%.
Pessimistic target level: 57.74
Optimistic target level: 59.58

Mirati Therapeutics Stock Forecast 06-22-2024.

Forecast target price for 06-22-2024: $59.58.
Positive dynamics for Mirati Therapeutics shares will prevail with possible volatility of 3.087%.
Pessimistic target level: 58.92
Optimistic target level: 60.80

Mirati Therapeutics Stock Forecast 06-23-2024.

Forecast target price for 06-23-2024: $60.17.
Positive dynamics for Mirati Therapeutics shares will prevail with possible volatility of 4.118%.
Pessimistic target level: 58.84
Optimistic target level: 61.37

MRTX (MRTX) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
Jul. 59.23 57.27 62.16 7.86
Aug. 67.14 61.40 74.79 17.91
Sep. 64.62 57.93 70.24 17.53
Oct. 60.16 55.47 67.11 17.35
Nov. 60.52 55.80 62.97 11.39
Dec. 66.15 61.39 71.90 14.63

Mirati Therapeutics forecast for this year


Mirati Therapeutics Stock Prediction for Jul 2024

An uptrend is forecast for this month with an optimal target price of $59.2283. Pessimistic: $57.27. Optimistic: $62.16


Mirati Therapeutics Stock Prediction for Aug 2024

An uptrend is forecast for this month with an optimal target price of $67.1353. Pessimistic: $61.40. Optimistic: $74.79


Mirati Therapeutics Stock Prediction for Sep 2024

An downtrend is forecast for this month with an optimal target price of $64.6177. Pessimistic: $57.93. Optimistic: $70.24


Mirati Therapeutics Stock Prediction for Oct 2024

An downtrend is forecast for this month with an optimal target price of $60.1591. Pessimistic: $55.47. Optimistic: $67.11


Mirati Therapeutics Stock Prediction for Nov 2024

An uptrend is forecast for this month with an optimal target price of $60.52. Pessimistic: $55.80. Optimistic: $62.97


Mirati Therapeutics Stock Prediction for Dec 2024

An uptrend is forecast for this month with an optimal target price of $66.1484. Pessimistic: $61.39. Optimistic: $71.90



Mirati Therapeutics (MRTX) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 74.68 66.62 77.93 14.52
Feb 73.79 69.47 76.88 9.64
Mar 73.23 69.06 77.52 10.91
Apr 81.47 75.48 86.60 12.84
May 74.14 71.25 81.37 12.44
Jun 65.24 60.15 71.41 15.76
Jul 64.07 59.93 68.10 11.99
Aug 70.51 63.00 75.58 16.65
Sep 70.29 67.45 73.46 8.18
Oct 68.29 62.96 70.34 10.49
Nov 63.68 57.85 66.07 12.43
Dec 72.66 64.05 76.69 16.49

Mirati Therapeutics (MRTX) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 81.82 72.86 86.60 15.87
Feb 76.54 70.11 81.82 14.31
Mar 66.21 64.12 68.59 6.52
Apr 69.28 64.09 76.25 15.95
May 61.59 59.56 66.12 9.92
Jun 57.16 52.19 60.67 13.99
Jul 55.79 49.93 62.40 19.98
Aug 52.19 47.26 55.09 14.21
Sep 58.06 54.58 60.41 9.66
Oct 56.32 49.56 61.22 19.04
Nov 54.21 49.17 60.63 18.91
Dec 53.15 50.20 57.45 12.63

Mirati Therapeutics (MRTX) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 53.47 48.34 59.00 18.08
Feb 53.79 51.85 59.28 12.52
Mar 56.77 51.84 59.58 13.01
Apr 53.88 48.22 60.02 19.66
May 50.81 48.37 52.41 7.71
Jun 53.09 47.20 59.31 20.41
Jul 57.08 51.77 62.56 17.24
Aug 58.79 54.73 64.79 15.52
Sep 58.17 55.38 63.67 13.02
Oct 54.07 50.91 55.69 8.59
Nov 51.39 45.69 56.64 19.33
Dec 53.86 49.34 57.25 13.83

Mirati Therapeutics (MRTX) Monthly Stock Prediction for 2028

Month Target Pes. Opt. Vol., %
Jan 57.25 54.59 63.35 13.83
Feb 53.22 51.14 56.25 9.08
Mar 53.86 48.69 57.73 15.67
Apr 57.98 54.32 60.41 10.08
May 55.98 49.76 59.08 15.77
Jun 61.27 56.30 68.53 17.84
Jul 57.04 54.56 59.86 8.86
Aug 58.24 54.31 61.99 12.40
Sep 62.87 55.70 66.45 16.18
Oct 53.91 51.40 57.30 10.30
Nov 54.23 50.98 56.35 9.53
Dec 55.78 53.77 57.53 6.54

Mirati Therapeutics information and performance

Mirati Therapeutics Address

N/A

Market Capitalization: N/A $

Market capitalization of the Mirati Therapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of MRTX shares in the company outstanding by the market price of one share.

EBITDA: N/A $

EBITDA of Mirati Therapeutics is earnings before interest, income tax and depreciation of assets.

PE Ratio: N/A

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: N/A

Price/earnings to growth

DPS: N/A

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: N/A

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: N/A

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: N/A
Trailing PE: N/A

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: N/A

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: N/A

Enterprise Value (EV) /Revenue

EV To EBITDA: N/A

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: N/A

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A



Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.